NCT00560989|Completed
Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis
Shared Genetic Susceptibility in CBD and Sarcoidosis
Loading search results
Shared Genetic Susceptibility in CBD and Sarcoidosis
Sponsor study identifier
Secondary identifiers
observational
400
1 country
1
Study Start
March 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
March 2007
Actual (reported)Granulomatous lung diseases are diseases in which inflamed clusters of white cells, known as granulomas, form in lung tissue. Chronic beryllium disease (CBD) and sarcoidosis are two granulomatous diseases that share similar clinical symptoms, physiological changes in the lungs, and immune responses to the disease. Genetic variations may make some people more susceptible to developing CBD or sarcoidosis. This study will identify common genetic regions associated with increased risk of developing the granulomatous diseases CBD and sarcoidosis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2007
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2007
Date type not reportedThis date has not been verified as actual or estimated.
March 2007
Actual (reported)November 16, 2007
Actual (reported)November 20, 2007
Actual (reported)Shared genetic regions associated with the risk of the granulomatous diseases CBD and sarcoidosis
Measured at completion of genetic analysis
Genetic/chromosomal regions associated with CBD and sarcoidosis
Measured at completion of genetic analysis
CBD cases
Beryllium-exposed, non-diseased control subjects
Sarcoidosis cases
Sarcoidosis control subjects
This study will use specimens from two well-established disease popultions: a CBD population previously recruited at the National Jewish Medical and Research Center and a sarcoidosis population derived from the previous NHLBI study, A Case-Control Etiologic Study of Sarcoidosis (ACCESS).
National Jewish Medical and Research Center
Denver, Colorado, 80206, United States
DNA specimens
Lisa A. Maier, MD, MSPH
National Jewish Health
400 participants (actual enrollment reported by the registry).
First Submitted
November 16, 2007
First Posted
November 20, 2007
Study Start
March 2007
Date type not reportedThis date has not been verified as actual or estimated.
Safety Study of Abatacept to Treat Refractory Sarcoidosis
Contact the study team to confirm eligibility.
Study Completion
March 2007
Actual (reported)Last Updated
September 26, 2014
Record last verified: 2014-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: